Skip to main content

Table 7 Risk factors correlated with overall survival in patients with specific histological types of appendiceal cancer

From: Chemotherapy in the treatment of different histological types of appendiceal cancers: a SEER based study

Variable

MAC

 

NMAC

 

SRCC

 

GCC

 

MiNENs

 
 

HR (95% CI)

P value

HR (95% CI)

P value

HR (95% CI)

P value

HR (95% CI)

P value

HR (95% CI)

P value

Age

  ≤ 56

1

 

1

 

1

 

1

 

1

 

  > 56

1.44 (1.22–1.69)

<.0001

1.45 (1.2–1.76)

0.0001

1.32 (1.02–1.71)

0.0381

1.6 (1.1–2.31)

0.0128

1.78 (1.14–2.79)

0.0116

Gender

 Male

1

         

 Female

0.71 (0.6–0.83)

<.0001

        

Marital status

 Married

1

 

1

     

1

 

 Unmarrieda

1.41 (1.19–1.66)

<.0001

1.51 (1.26–1.8)

<.0001

    

2.12 (1.33–3.37)

0.0015

 Unknown

1.18 (0.75–1.85)

0.4711

1.42 (0.93–2.17)

0.1067

    

1.15 (0.44–3.02)

0.7828

Race

 African American

      

1

   

 White

      

0.44 (0.27–0.71)

0.0008

  

 Other

      

0.15 (0.03–0.65)

0.0114

  

 Unknown

      

0!

0.9752

  

Region

 West

1

 

1

       

 South

1.25 (1.03–1.52)

0.0224

1.39 (1.13–1.71)

0.0021

      

 Midwest

1.49 (1.15–1.93)

0.0027

1.14 (0.83–1.57)

0.4065

      

 Northwest

1.02 (0.81–1.28)

0.886

1.08 (0.84–1.38)

0.5372

      

CEA

 Negative

1

 

1

 

1

     

 Positive

1.36 (1.06–1.75)

0.0168

1.49 (1.14–1.95)

0.0035

1.62 (1.13–2.32)

0.009

    

 Unknown

0.89 (0.7–1.12)

0.3117

1.27 (1–1.6)

0.046

1.12 (0.83–1.52)

0.4668

    

Deposit

 Negative

1

 

1

   

1

   

 Positive

1.75 (1.31–2.33)

0.0001

1.38 (1.02–1.86)

0.0365

  

2.59 (1.29–5.19)

0.0074

  

 Unknown

1.15 (0.95–1.38)

0.1512

1.32 (1.08–1.61)

0.0059

  

1.25 (0.86–1.82)

0.2347

  

Harvested lymph nodes

  ≤ 12

1

 

1

 

1

 

1

 

1

 

  > 12

0.64 (0.54–0.75)

<.0001

0.6 (0.49–0.73)

<.0001

0.65 (0.49–0.85)

0.0016

0.51 (0.34–0.77)

0.0015

0.31 (0.19–0.49)

<.0001

 Unknown

0.59 (0.32–1.08)

0.0866

1.27 (0.66–2.42)

0.4734

1.25 (0.3–5.22)

0.761

4.46 (0.56–35.46)

0.1572

1.97 (0.44–8.92)

0.3789

T stage

 T1

1

 

1

1

1.74 (0.76–3.96)

0.189

0.65 (0.32–1.33)

0.2409

0.74 (0.17–3.15)

0.6795

 T2

1.21 (0.72–2.03)

0.4692

0.97 (0.67–1.41)

0.8767

1.42 (0.5–4.04)

0.5097

0.32 (0.12–0.88)

0.0267

0.77 (0.1–6.08)

0.7997

 T3

1.47 (1.03–2.1)

0.0363

0.58 (0.4–0.83)

0.0027

1

 

1

 

1

 

 T4

1.78 (1.27–2.49)

0.0009

1.45 (1.18–1.79)

0.0005

2.53 (1.74–3.69)

<.0001

1.08 (0.67–1.74)

0.7398

2.1 (1.26–3.51)

0.0046

N stage

 N0

1

 

1

 

1

 

1

 

1

 

 N1

2.09 (1.66–2.61)

<.0001

1.97 (1.57–2.47)

<.0001

1.74 (1.23–2.46)

0.0016

2.28 (1.28–4.05)

0.0052

2.38 (1.26–4.49)

0.0075

 N2

3.3 (2.47–4.4)

<.0001

2.66 (2.03–3.47)

<.0001

2.3 (1.65–3.2)

<.0001

4.39 (2.26–8.53)

<.0001

5.66 (2.98–10.73)

<.0001

M stage

 M0

1

 

1

 

1

 

1

 

1

 

 M1

0.63 (0.52–0.76)

<.0001

2.56 (2.02–3.26)

<.0001

0.46 (0.33–0.63)

<.0001

0.31 (0.17–0.58)

0.0002

0.32 (0.19–0.52)

<.0001

Grade

 Well differentiated

1

 

1

 

0.65 (0.13–3.23)

0.593

  

1

 

 Moderately differentiated

1.58 (1.3–1.92)

<.0001

1.48 (1.06–2.07)

0.0205

1

   

2.21 (0.61–7.93)

0.2253

 Poorly or un-differentiated

2.28 (1.75–2.96)

<.0001

1.96 (1.38–2.79)

0.0002

2.67 (1.17–6.09)

0.0192

  

4.26 (1.41–12.88)

0.0102

 Unknown

1.65 (1.3–2.09)

<.0001

1.93 (1.27–2.92)

0.0021

3.25 (1.39–7.59)

0.0065

  

2.99 (0.97–9.21)

0.0569

Surgery

 Less than hemicolectomy

  

1

   

1

   

 Hemicolectomy or more

  

0.71 (0.59–0.86)

0.0004

  

0.65 (0.44–0.96)

0.0292

  

 Other

  

1.7 (1.19–2.41)

0.0034

  

1.95 (0.97–3.96)

0.0628

  

Chemotherapy

 No

1

 

1

 

1

 

1

 

1

 

 Yes

0.72 (0.61–0.86)

0.0003

0.61 (0.49–0.76)

<.0001

0.62 (0.46–0.84)

0.002

1.29 (0.76–2.19)

0.352

1.07 (0.63–1.8)

0.8081

  1. aUnmarried status, including divorced, separated, widowed and unmarried. CI confidence interval; HR hazard ratio; SRCC signet ring cell carcinoma; MAC mucinous adenocarcinomas; NMAC non-mucinous adenocarcinoma; MiNENs mixed neuroendocrine non-neuroendocrine neoplasms; GCC goblet cell carcinoma; NETs neuroendocrine tumors; NECs neuroendocrine carcinomas